← ANALYST RATINGS · TIPRANKS
Omeros (OMER): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy1 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $27.50, the highest $33.00, the lowest $22.00. The average is +69.8% from the last price of $16.20.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $22.00 → $17.00−22.7% | Hold | +4.9% | Downgrade | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $21.00 → $16.00−23.8% | Hold | −1.2% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $20.50 → $17.00−17.1% | Hold | +4.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $20.00 → $16.50−17.5% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $22.00 → $17.00−22.7% | Hold | +4.9% | Downgrade | 17.10.26on TipRanks 15:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $19.50 → $16.00−17.9% | Hold | −1.2% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $33.00 | Buy | +103.7% | Reiterated | 16.10.26on TipRanks 12:30 | −12.7% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $22.00 | Buy | +35.8% | Reiterated | 14.10.26on TipRanks 07:50 | −1.3%next day +1.7% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | — | Hold | — | Reiterated | 13.08.26on TipRanks 05:55 | +25.9%next day −0.7% · 5 days +9.3% | ↗ |
| Stephen Brozak★★★★★★★★★★#2946 · hits 42% · avg +10.5% | WBB Securities | $45.00 → $55.00+22.2% | Buy | +239.5% | Reiterated | 08.01.26on TipRanks 09:10 | −4.5%next day −7.8% · 5 days −9.6% | ↗ |
| Jason Kolbert★★★★★★★★★★#12335 · hits 32% · avg −9.0% | D. Boral Capital | $36.00 | Buy | +122.2% | Reiterated | 24.12.25on TipRanks 11:00 | +75.2%next day +2.3% · 5 days +7.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Omeros
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $27.50 at a price of $19.04 (+44.4%); now: $27.50 at $16.20 (+69.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 5 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 1 | 2 |
| Hold | 2 | 3 | 3 | 3 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.02 (from $0.02 to $0.02). Last quarter: $0.15.
Sales
Next quarter’s sales estimate — $37M (from $31M to $41M). Last quarter: $29M.
Best top-analyst consensus in the sector · Healthcare
About Omeros
- CEO: Gregory A. Demopulos
- Employees: 175
- The Omeros Building, Seattle, WA, 98119, US
- www.omeros.com
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indi
Data from the stock’s TipRanks forecast page, read 78 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗